Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reversal of New Oral Anticoagulants with Coagulation Factors
NCT01478282Phase 4Unknown
- Start
- Jan 2012
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rivaroxaban and dabigatran etexilate oral solution in thrombosis (2 arms). Primary endpoints: Modifications in hemostasis parameters at 5 days and Changes observed after in vitro addition of coagulation factor concentrates at 5 days. Status: unknown.
02
Drugs
rivaroxabandabigatran etexilate oral solution
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT01478282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01478282.